Perrigo Co. plc (NYSE: PRGO) is adding generic forms of Retin-A, often prescribed as an anti-aging or acne-treatment skin cream, from Matawan Pharmaceuticals LLC for an undisclosed amount.

The Retin-A treatment had $287 million in sales for the 12 months ending October 2015. The seller is a subsidiary of Rouses Point Pharmaceuticals LLC, a Bonita Springs, Florida-based generics business.  

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.